Acupuncture therapy for myalgia-type temporomandibular joint disorders and its central mechanisms

注册号:

Registration number:

ITMCTR2025000769

最近更新日期:

Date of Last Refreshed on:

2025-04-17

注册时间:

Date of Registration:

2025-04-17

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

肌痛型颞下颌关节紊乱病的针刺治疗及其中枢机制研究

Public title:

Acupuncture therapy for myalgia-type temporomandibular joint disorders and its central mechanisms

注册题目简写:

English Acronym:

研究课题的正式科学名称:

肌痛型颞下颌关节紊乱病的针刺治疗及其中枢机制研究

Scientific title:

Acupuncture therapy for myalgia-type temporomandibular joint disorders and its central mechanisms

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

沈观

研究负责人:

楚佳梅

Applicant:

Guan Shen

Study leader:

Jiamei Mei

申请注册联系人电话:

Applicant telephone:

13735858778

研究负责人电话:

Study leader's telephone:

1316152740

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2935339065@qq.com

研究负责人电子邮件:

Study leader's E-mail:

Chujiamei73@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市西湖区体育场路453号

研究负责人通讯地址:

浙江省杭州市西湖区体育场路453号

Applicant address:

No. 453 Stadium Road Xihu District Hangzhou City Zhejiang Province

Study leader's address:

No. 453 Stadium Road Xihu District Hangzhou City Zhejiang Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江中医药大学附属杭州市中医院

Applicant's institution:

Hangzhou Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024KKL120

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

杭州市中医院科研伦理委员会

Name of the ethic committee:

The Research Ethics Committee of Hangzhou Municipal Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024/6/6 0:00:00

伦理委员会联系人:

张来

Contact Name of the ethic committee:

Lai Zhang

伦理委员会联系地址:

浙江省杭州市西湖区体育场路453号八号楼6楼627室

Contact Address of the ethic committee:

Room 627 6th Floor Building 8 No. 453 Stadium Road Xihu District Hangzhou City Zhejiang Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 135 8872 7528

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zhanglai1110@qq.com

研究实施负责(组长)单位:

浙江中医药大学附属杭州市中医院

Primary sponsor:

Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University

研究实施负责(组长)单位地址:

浙江省杭州市西湖区体育场路453号

Primary sponsor's address:

No. 453 Stadium Road Xihu District Hangzhou City Zhejiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

杭州市

Country:

China

Province:

Zhe Jiang

City:

Hang Zhou

单位(医院):

浙江中医药大学附属杭州市中医院

具体地址:

浙江省杭州市西湖区体育场路453号

Institution
hospital:

Hangzhou Hospital of Traditional Chinese Medicine

Address:

No. 453 Stadium Road Xihu District Hangzhou City Zhejiang Province

经费或物资来源:

杭州市卫生健康委员会

Source(s) of funding:

Hangzhou Municipal Health Commission

研究疾病:

颞下颌关节紊乱病

研究疾病代码:

Target disease:

Temporomandibular Disorders

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

(1)客观评价针刺治疗TMDM的临床疗效,提供针刺治疗TMDM的可视化疗效证据,从而更好的指导临床治疗,提高TMDM的临床疗效,为针灸临床治疗TMDM提供诊疗方案。 (2)基于fMRI技术,观察针刺治疗对TMDM患者脑功能区激活的影响,初步探索针刺治疗TMDM的中枢效应机制。

Objectives of Study:

(1) Objectively evaluate the clinical efficacy of acupuncture in the treatment of TMDM and provide visual evidence of the efficacy of acupuncture in the treatment of TMDM so as to better guide the clinical treatment improve the clinical efficacy of TMDM and provide diagnosis and treatment plans for the clinical treatment of TMDM in acupuncture. (2) Based on fMRI technology the effect of acupuncture therapy on the activation of brain functional areas in TMDM patients was observed and the central effect mechanism of acupuncture treatment of TMDM was preliminarily explored.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.符合DC/TMD中TMDM诊断标准。 2.VAS疼痛评分≥4分的患者; 3.年龄在18—60岁,能配合治疗及检查的患者; 4.未在其他医院或机构接受过针刺治疗; 5.近一个月未接受过TMDM的相关治疗; 6.右利手; 7.签署知情同意书,配合治疗,能按计划坚持完成全部治疗者。 8.健康对照组纳入标准如下:① 不符合DC/TMD中任何颞下颌关节疾病(含TMDM)诊断标准;② 颞下颌关节区无疼痛或功能障碍(VAS疼痛评分≤1分);③ 年龄18—60岁,右利手;④ 性别比例与治疗组保持一致;⑤ 无严重基础疾病(心、肺、肝、肾功能正常);⑥ 近1个月未接受过颞下颌关节相关治疗或药物干预。⑦ 签署知情同意书,承诺配合研究流程。

Inclusion criteria

1. Meet the diagnostic criteria for TMDM in DC/TMD; 2. Patients with VAS pain score ≥4 points; 3. Patients aged 18-60 years old who can cooperate with treatment and examination; 4. Have not received acupuncture treatment in other hospitals or institutions; 5. Have not received TMDM related treatment in the past month; 6. Right hand; 7. Those who signed the informed consent form cooperated with the treatment and were able to complete all the treatment as planned; 8.‌Inclusion Criteria for Healthy Control Group‌: ① No diagnosis of any temporomandibular joint disorders (including TMDM) according to DC/TMD criteria; ② Absence of pain or dysfunction in the temporomandibular joint region (VAS pain score ≤1); ③ Age 18–60 years right-handed; ④ Gender ratio matched to the treatment group; ⑤ No severe underlying systemic diseases (normal cardiac pulmonary hepatic and renal function); ⑥ No temporomandibular joint-related treatments or pharmacological interventions within the past month; ⑦ Signed informed consent with commitment to comply with the study protocol.

排除标准:

1.有颞下颌关节外伤或手术史; 2.有颞下颌肿瘤、自身免疫性骨关节系统疾病; 3.合并有严重的基础疾病(如心、肺、肝、肾功能障碍者),或严重危及生命; 4.在服用特定药物的人群(如正在服用抗抑郁或抗精神分裂的药物者或同时应用非甾体消炎药、肌肉松弛药者); 5.特殊人群(如孕妇、凝血功能障碍易出血的患者等); 6.有其他不能配合治疗的疾病与因素; 7.‌健康对照组排除标准与上述排除标准一致。

Exclusion criteria:

1. History of temporomandibular joint trauma or surgery; 2. Temporomandibular tumors autoimmune osteoarticular system diseases; 3. Patients with serious underlying diseases (such as heart lung liver and kidney dysfunction) or severe life-threatening; 4. People taking specific drugs (such as those who are taking antidepressant or anti-schizophrenic drugs or those who are taking non-steroidal anti-inflammatory drugs and muscle relaxants at the same time); 5. Special populations (such as pregnant women patients with coagulation dysfunction and easy bleeding etc.); 6. There are other diseases and factors that cannot be treated together; 7.The exclusion criteria for the healthy control group align with the aforementioned exclusion criteria for the treatment group.

研究实施时间:

Study execute time:

From 2024-09-01

To      2027-03-31

征募观察对象时间:

Recruiting time:

From 2025-04-30

To      2026-12-31

干预措施:

Interventions:

组别:

健康对照组

样本量:

10

Group:

Healthy control group

Sample size:

干预措施:

无干预措施

干预措施代码:

Intervention:

No intervention

Intervention code:

组别:

针刺组

样本量:

35

Group:

Acupuncture group

Sample size:

干预措施:

取穴:下关、颊车、听宫、颧髎、翳风、合谷、太阳 操作方法:患者仰卧位,局部穴位皮肤常规消毒后,采用 0.25×40mm 毫针直刺25-30mm,进针后行提插、捻转平补平泻手法,针刺得气,针感以酸、麻、胀、重为度(可合并出现,亦可单一出现)。留针 30 min。

干预措施代码:

Intervention:

Acupuncture points: Xiaguan cheek car Tinggong cheeks pamper Hegu sun Operation method: The patient is in the supine position after the routine disinfection of the skin of the local acupuncture points the 0.25×40mm millineedle is used to puncture 25-30mm and the needle is inserted and twisted to make up for the laxative technique and the acupuncture is qi and the needle feeling is sour numb swollen and heavy .Leave the needle on for 30 minutes

Intervention code:

组别:

假针刺组

样本量:

35

Group:

Sham acupuncture group

Sample size:

干预措施:

假针灸针(0.25×40 mm,不锈钢材质,钝头)在仰卧位患者常规皮肤消毒后,以与针刺组相同的穴位进行刺激,施加压力时无法刺入皮肤,留针30分钟。

干预措施代码:

Intervention:

Sham acupuncture needles (0.25×40 mm, stainless steel with blunt tips) were applied to acupoints (identical to the acupuncture group) in supine patients for 30 minutes following routine skin disinfection, preventing skin penetration under pressure.

Intervention code:

样本总量 Total sample size : 80

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

浙江省

市(区县):

杭州市

Country:

China

Province:

Zhe Jiang

City:

Hang Zhou

单位(医院):

浙江中医药大学附属杭州市中医院

单位级别:

三甲

Institution/hospital:

Hangzhou Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

局部 一致性分析

指标类型:

主要指标

Outcome:

regional homogeneity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

压力疼痛阈值

指标类型:

次要指标

Outcome:

Pressure Pain Threshold

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑功能连接

指标类型:

主要指标

Outcome:

Functional Connectivity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

最大张口度

指标类型:

次要指标

Outcome:

Maximum active mouth opening

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

下颌功能限制量表

指标类型:

次要指标

Outcome:

Jaw Functional Limitation Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

采用疼痛视觉模拟评分法

指标类型:

主要指标

Outcome:

visual analogue scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低频振幅

指标类型:

主要指标

Outcome:

amplitude of low-frequency fluctuation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 60
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究为单中心、随机、对照研究。符合标准的70例患者将以1:1的比例随机分配到针刺组和假针刺组中。由第三方医药科技开发有限公司的软件产生随机分配序列,将受试者就诊顺序与随机数字进行匹配并完成分组。将顺序号对应分组装入不透明信封内,完成受试者的干预分配。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study is a single-center randomized controlled trial. Seventy eligible patients will be randomly allocated to either the verum acupuncture group or the sham acupuncture group in a 1:1 allocation ratio. The randomization sequence will be generated by software provided by Third-Party Pharmaceutical Technology Development Co. Ltd. with group assignments matched to participants based on their visit sequence. Sequentially numbered sealed opaque envelopes containing allocation information will be used to ensure concealed allocation prior to participant enrollment.

盲法:

由于针灸试验的特殊性,无法做到盲操作者,故本研究采用盲患者、盲评价者和统计者三个层次的盲法。治疗过程予单个隔离治疗空间治疗,避免患者之间交流比较等方式最大可能的对患者实行盲法。盲评价者,由不知分组情况的第三者进行疗效评价。最后盲统计分析者,实行研究者、操作者、统计者三分离。

Blinding:

Due to the particularity of acupuncture and moxibustion trials blind operators could not be blinded so three levels of blinding methods were used in this study: blind patients blind evaluators and statisticians. During the treatment process the treatment was carried out in a single isolated treatment space to avoid communication and comparison between patients and the blinding of patients was carried out to the greatest extent possible. For blind evaluators the efficacy evaluation will be conducted by a third party who does not know the grouping situation. Finally blind statistical analysts are separated from researchers operators and statisticians.

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1.数据收集方法 本研究所有参与结局评估人员均接受集体培训,详细界定定性数据的问题含义,定量指标通过使用相同器械重复测量三次取平均值的方式提高数据质量。本研究采用的所有评估器械均具有较高的信度及效度。 2.数据管理 录入、编码、保密及储存的方案,包括任何用来提高数据质量的相关措施(如双重录入、资料值的范围检查)。研究者应当按照研究方案的要求,将收集的数据记入CRF表,并由第三方医药科技开发有限公司的软件进行数据记录和数据管理,确保临床试验数据的真实性,完整性,准确性。研究结束时,研究者必须向数据管理中心提交本研究选定的所有患者的病例报告,这些病例报告必须完整并签名。检查收集的案例报告表数据的一致性,对不一致的数据发出疑问表,需要研究者进行解释。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. Data Collection Methods All participants in the outcome assessor were trained to define the meaning of qualitative data in detail and quantitative measures were used to improve data quality by using repeated measures of the same instrument and averaging them three times. All evaluation devices used in this study had high reliability and validity. 2. Data management Entry encoding confidentiality and storage solutions including any measures to improve data quality (e.g. double entry range checking of data values). The investigator shall in accordance with the requirements of the research protocol record the collected data in the CRF form and the software of the third-party medical technology development Co. Ltd. shall record and manage the data to ensure the authenticity completeness and accuracy of the clinical trial data. At the end of the study the investigator must submit to the Data Management Center the case reports of all patients selected for this study which must be complete and signed. Check the consistency of the collected case report form data and issue a question sheet for inconsistent data which requires interpretation by the researcher.

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above